Market Research Logo

Varicella Zoster Infection Treatment Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)

Varicella Zoster Infection Treatment Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)

Varicella zoster spreads easily from people with chickenpox to others who never had the disease or been vaccinated. It can be transmitted by respiratory droplets, from skin lesions, by direct contact or possibly by aerosolisation of the virus from skin lesions. Chickenpox can spread from people with shingles to others who never had chickenpox or received the chickenpox vaccine. According to a study of the Centers of Disease Control and Prevention, transmission of varicella is high among household members. About 90% of varicella cases are susceptible to close contact with people suffering from varicella. In schools and day care centres the transmission rate among susceptible children tend to be lower than 30%–50%. Varicella occurs worldwide with ongoing endemic transmission in areas where the population is sufficiently large to support such transmission.

Purchase of drugs through hospital pharmacies to increase in the coming years

Pregnant women, kids, and the geriatric population have the highest risks of developing a varicella zoster infection. As a result, if any person or kid is infected, they are either admitted or prescribed specific medicines or drugs for the treatment of the varicella zoster infection. Some of the medicines are only sold by hospital pharmacies as these medicines can only be bought if prescribed by a doctor or medical practitioner. Stringent regulations are also another reason for an increasing number of purchases from hospital pharmacies. The FDA regulatory approval process for drugs is strict. Therefore, these challenges in the regulatory environment are prompting investors in the industry to shift their investments overseas, which may act as a restraint for the growth of the varicella zoster infection treatment market. Most of the companies are facing difficulties in bringing herpes zoster drugs and vaccines to the market without the necessary FDA approvals. As a result, the approved drugs can only be bought if prescribed by a qualified healthcare professional and from specific hospital pharmacies. Retail pharmacies to get a boost with increasing healthcare expenditure and an advanced healthcare model

According to the IMF, global healthcare expenditure is expected to increase by over 6% yearly, based on the current GDP forecast. The rising geriatric population in developed countries and growing affluence in emerging markets are likely to boost healthcare expenditure. In the U.S., prescription drugs comprise 10% of the national health expenditure and this is expected to increase in the coming years. Besides, high spending on prescription drugs is attributed to the increased spending on new medicines, increased spending on generics, price rise of existing branded drugs, and fewer expensive blockbuster drugs going off-patent.

The governments and regulatory bodies of several countries are adopting various cost containment measures to reduce the healthcare burden, especially in developed economies. This change from a volume- to a value-based system is driven by various measures taken by the governments, healthcare providers, payers and pharmaceutical companies, which include outcome-based pricing, profit and risk sharing, price control and competitive tendering. The value-based healthcare model is expected to help achieve supreme value for money spent on healthcare and thus improve the outcomes through integrated care pathways. Nevertheless, at the same time it would levy pricing pressure on biopharmaceutical and medtech companies, which may impact R&D investment for innovative medical treatment technologies. As a result of all these factors, the demand for bulk medicines is increasing and as retail pharmacies are the best place to obtain medicines in bulk, these pharmacies are getting a good push in the global market.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. Wheel of Fortune
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Varicella Zoster Infection Treatment Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
5. Global Economic Outlook
5.1. Disease Outlook
6. Key Inclusions
6.1. Key Manufacture List
6.2. Prescription Pattern
7. North America Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
7.1. Introduction
7.2. Regional Market Trends
7.3. Regional Scenario
7.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
7.4.1. U.S.
7.4.2. Canada
7.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
7.6. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
7.6.1. Acyclovir
7.6.2. Valacyclovir
7.6.3. Famciclovir
7.7. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
7.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
7.8.1. Oral
7.8.2. Topical
7.8.3. Injectable
7.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
7.10. Historical Market Size (US$ Mn) and Volume Trend Analysis By Distribution Channel, 2012–2016
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Online Pharmacies
7.10.4. Drug Stores
7.11. Market Size (US$ Mn) and Volume Forecast By Distribution Channel, 2017–2025
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Drug Type
7.12.3. By Route of Administration
7.12.4. By Distribution Channel
7.13. Key Market Participants – Intensity Mapping
8. Latin America Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
8.1. Introduction
8.2. Regional Market Trends
8.3. Regional Scenario
8.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
8.6. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
8.6.1. Acyclovir
8.6.2. Valacyclovir
8.6.3. Famciclovir
8.7. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
8.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
8.8.1. Oral
8.8.2. Topical
8.8.3. Injectable
8.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
8.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Online Pharmacies
8.10.4. Drug Stores
8.11. Market Size (US$ Mn Forecast By Distribution Channel, 2017–2025
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Drug Type
8.12.3. By Route of Administration
8.12.4. By Distribution Channel
8.13. Key Market Participants – Intensity Mapping
9. Western Europe Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
9.1. Introduction
9.2. Regional Market Trends
9.3. Regional Scenario
9.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Western Europe
9.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
9.6. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
9.6.1. Acyclovir
9.6.2. Valacyclovir
9.6.3. Famciclovir
9.7. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
9.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
9.8.1. Oral
9.8.2. Topical
9.8.3. Injectable
9.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
9.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacies
9.10.3. Online Pharmacies
9.10.4. Drug Stores
9.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Drug Type
9.12.3. By Route of Administration
9.12.4. By Distribution Channel
9.13. Key Market Participants – Intensity Mapping
10. Eastern Europe Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
10.1. Introduction
10.2. Regional Market Trends
10.3. Regional Scenario
10.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
10.4.1. Russia
10.4.2. Poland
10.4.3. Rest of Eastern
10.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
10.6. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
10.6.1. Acyclovir
10.6.2. Valacyclovir
10.6.3. Famciclovir
10.7. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
10.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
10.8.1. Oral
10.8.2. Topical
10.8.3. Injectable
10.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
10.10.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Pharmacies
10.10.4. Drug Stores
10.11.Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
10.12.Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Drug Type
10.12.3. By Route of Administration
10.12.4. By Distribution Channel
10.13.Key Market Participants – Intensity Mapping
11. Asia Pacific Excluding China & Japan Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
11.1. Introduction
11.2. Regional Scenario
11.3. Regional Market Trends
11.4. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
11.4.1. India
11.4.2. Australia and New Zealand
11.4.3. ASEAN
11.4.4. Rest of APECJ
11.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
11.6. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
11.6.1. Acyclovir
11.6.2. Valacyclovir
11.6.3. Famciclovir
11.7. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
11.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
11.8.1. Oral
11.8.2. Topical
11.8.3. Injectable
11.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
11.10.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Pharmacies
11.10.4. Drug Stores
11.11.Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
11.12.Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Drug Type
11.12.3. By Route of Administration
11.12.4. By Distribution Channel
11.13.Key Market Participants – Intensity Mapping
12. China Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
12.1. Introduction
12.2. Key Regulations
12.3. Regional Market Trends
12.4. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
12.4.1. Acyclovir
12.4.2. Valacyclovir
12.4.3. Famciclovir
12.5. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
12.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
12.6.1. Oral
12.6.2. Topical
12.6.3. Injectable
12.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
12.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.8.4. Drug Stores
12.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
12.10.Market Attractiveness Analysis
12.10.1. By Country
12.10.2. By Drug Type
12.10.3. By Route of Administration
12.10.4. By Distribution Channel
12.11.Key Market Participants – Intensity Mapping
13. Japan Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
13.1. Introduction
13.2. Key Regulations
13.3. Regional Market Trends
13.4. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
13.4.1. Acyclovir
13.4.2. Valacyclovir
13.4.3. Famciclovir
13.5. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
13.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
13.6.1. Oral
13.6.2. Topical
13.6.3. Injectable
13.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
13.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.8.4. Drug Stores
13.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
13.10.Market Attractiveness Analysis
13.10.1. By Country
13.10.2. By Drug Type
13.10.3. By Route of Administration
13.10.4. By Distribution Channel
13.11.Key Market Participants – Intensity Mapping
14. Middle East & Africa Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
14.1. Introduction
14.2. Regional Scenario
14.3. Regional Market Trends
14.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
14.4.1. GCC Countries
14.4.2. North Africa
14.4.3. South Africa
14.4.4. Rest of MEA
14.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
14.6. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
14.6.1. Acyclovir
14.6.2. Valacyclovir
14.6.3. Famciclovir
14.7. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
14.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
14.8.1. Oral
14.8.2. Topical
14.8.3. Injectable
14.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
14.10.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.10.4. Drug Stores
14.11.Market Size (US$ Mn) By Distribution Channel, 2017–2025
14.12.Market Attractiveness Analysis
14.12.1. By Country
14.12.2. By Drug Type
14.12.3. By Route of Administration
14.12.4. By Distribution Channel
14.13.Key Market Participants – Intensity Mapping
15. Forecast Factors: Relevance and Impact
16. Forecast Assumptions
17. Competition Analysis
17.1. Competition Dashboard
17.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
17.2.1. Teva Pharmaceutical Industries Ltd.
17.2.2. Abbott Laboratories
17.2.3. Sun Pharmaceuticals Industries Ltd.
17.2.4. Mylan N.V.
17.2.5. Pfizer Inc.
17.2.6. GlaxoSmithKline plc.
17.2.7. Dr. Reddy’s Laboratories, ltd.
17.2.8. Novartis AG
17.2.9. Valeant Pharmaceuticals International Inc.
18. Global Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025, By Region
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2016
18.3. Market Size (US$ Mn) Forecast By Region, 2017–2025
18.3.1. North America
18.3.2. Latin America
18.3.3. Western Europe
18.3.4. Eastern Europe
18.3.5. Asia Pacific Excluding China & Japan
18.3.6. China
18.3.7. Japan
18.3.8. Middle East & Africa
18.4. Market Attractiveness Analysis By Region
19. Global Varicella Zoster Infection Treatment Analysis 2012–2016 and Forecast 2017–2025, By Drug Type
19.1. Introduction/Key Findings
19.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
19.2.1. Acyclovir
19.2.2. Valacyclovir
19.2.3. Famciclovir
19.3. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
19.4. Market Attractiveness Analysis By Drug Type
20. Global Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025, By Route of Administration
20.1. Introduction/Key Findings
20.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
20.2.1. Oral
20.2.2. Topical
20.2.3. Injectable
20.3. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
20.4. Market Attractiveness Analysis By Route of Administration
21. Global Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025, By Distribution Channel
21.1. Introduction/Key Findings
21.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
21.2.1. Hospital Pharmacies
21.2.2. Retail Pharmacies
21.2.3. Online Pharmacies
21.2.4. Drug Stores
21.3. Market Size (US$ Mn) By Distribution Channel, 2017–2025
21.4. Market Attractiveness Analysis By Distribution Channel
22. Global Varicella Zoster Infection Treatment Market Analysis 2012–2016 and Forecast 2017–2025
22.1. Market Value Share Analysis By All Segment
22.2. Y-o-Y Growth Analysis By All Segment
22.3. Absolute $ Opportunity

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report